Type of security: Stock
Sector: Health Care
Industry: Medical/Dental Instruments
The data is delayed by 15 minutes.
ATOS is in the long-term down -100% below S&P in 9 years.
Description: Atossa Genetics, Inc. operates as a healthcare company that focuses on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer in the United States. Its diagnostic tests include the ForeCYTE Breast Health Test, which provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65; and the ArgusCYTE Breast Health Test that offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company also intends to offers FullCYTE Breast Health Test, which is in development to assess the individual breast ducts for pre-cancerous changes in women; and NextCYTE Breast Cancer Test that is in the prevalidation phase to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. Atossa Genetics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-2.28||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||18630%||Sales Growth - Q/Q||283.03%||P/E||-0.22|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-112.88%||ROE||-151.51%||ROI|
|Current Ratio||3.26||Quick Ratio||3.23||Long Term Debt/Equity||Debt Ratio||0.34|
|Gross Margin||Operating Margin||-653.31%||Net Profit Margin||-656.04%||Dividend Payout Ratio|
|Cash From Financing Activities||4.29 M||Cash From Investing Activities||-70 K||Cash From Operating Activities||-3 M||Gross Profit||670 K|
|Net Profit||-3.34 M||Operating Profit||-3.28 M||Total Assets||13.8 M||Total Current Assets||11.37 M|
|Total Current Liabilities||3.49 M||Total Debt||110 K||Total Liabilities||3.52 M||Total Revenue||1.87 M|
|High 52 week||7.07||Low 52 week||0.92||Last close||2.54||Last change||0.79%|
|RSI||29.7||Average true range||0.16||Beta||0.87||Volume||177.7 K|
|Simple moving average 20 days||-11.13%||Simple moving average 50 days||-18.15%||Simple moving average 200 days||31.2%|
|Performance Week||-1.93%||Performance Month||-3.05%||Performance Quart||68.21%||Performance Half||96.9%|
|Performance Year||-49.34%||Performance Year-to-date||149.02%||Volatility daily||6.28%||Volatility weekly||14.04%|
|Volatility monthly||28.78%||Volatility yearly||99.7%||Relative Volume||171.06%||Average Volume||3.09 M|
|New High||New Low|
2019-10-15 08:30:00 | Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia
2019-07-17 08:30:00 | Atossa Genetics Provides Information on FDA Expanded Access Policy and Requests
2019-06-28 11:38:23 | A Look At Benzinga Pro's Most-Searched Tickers For June 28, 2019
2019-06-19 15:56:16 | Some Atossa Genetics NASDAQ:ATOS Shareholders Have Copped A 99% Share Price Wipe Out
2019-05-30 08:00:00 | Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019
2019-04-30 06:10:00 | _The Digital Economy & World Markets_
2019-04-22 08:45:00 | Reducing This Amino Acid May Aid In Fight Against Breast Cancer
2019-03-28 16:30:00 | Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update
2019-03-27 10:15:00 | _Bull Market Hopping?_
2019-03-18 08:30:00 | Atossa Genetics Announces Receipt of $10 Million
2019-03-14 13:01:36 | What Type Of Shareholder Owns Atossa Genetics Inc.’s NASDAQ:ATOS?
2019-03-14 12:53:31 | Atossa Genetics News: FDA Approval Sends ATOS Stock Skyrocketing
2019-02-07 08:30:00 | Atossa Genetics Reports Results From “Expanded Access” Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues
2019-01-30 09:15:00 | Vista Partners January 2019 Monthly Macroeconomic and Investment Newsletter
2019-01-09 11:58:00 | 4 Healthcare Stocks Looking To Set January Highs
2018-12-28 07:20:00 | Detailed Research: Economic Perspectives on American Airlines Group, Sandstorm Gold, Kala Pharmaceuticals, Adecoagro S.A, Novagold Resources, and Atossa Genetics — What Drives Growth in Today's Competitive Landscape
2018-12-19 08:05:00 | _The Roller Coaster Ride Continues_
2018-12-07 12:07:13 | Edison issues outlook on Atossa Genetics ATOS
2018-10-25 09:10:00 | Report: Exploring Fundamental Drivers Behind Atossa Genetics, Titan International, Olympic Steel, L Brands, Sysco, and TiVo — New Horizons, Emerging Trends, and Upcoming Developments
2018-09-26 09:05:00 | ''Superfirms' Domination Influences Economic Factors''
2018-09-14 09:10:00 | An Interview with Atossa CEO Steven Quay MD, Ph.D. Titled, _What Is Gynecomastia?_
2018-08-23 09:02:00 | ''Robust Economy, Resilient Market''
2018-08-21 09:05:00 | _What Is Intraductal Immuno-oncology & CAR-T Cell Therapy?_